Compare Range Nuclear Renaissance ETF (NUKZ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Range Nuclear Renaissance ETF vs Novartis AG — how do they compare? Range Nuclear Renaissance ETF trades at $66.18, while Novartis AG trades at $139.36 (market cap $262.64B). The key difference: Novartis AG pays a 3.44% dividend while Range Nuclear Renaissance ETF pays none. Which is the better fit depends on your goals.
| NUKZ | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $76.23 | $168.62 |
52-Week Low | $59.84 | $121.80 |
Market Cap | — | $262.64B |
Enterprise Value | — | $303.97B |
Dividend Yield | — | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.
The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Range Nuclear Renaissance ETF
Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.
Read more on NUKZ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
